Arvinas recently signed a blockbuster $2.4 billion deal with Pfizer. The bankroll will fund additional trials of the Arvinas breast cancer drug, alone and in combination with Pfizer’s Ibrance product, all leading toward the start of stage 3 trials in the second half of the year.
Consequently, Arvinas is on a hiring spree that is expected to double the workforce from today’s 275 employees.
Arvinas was founded in 2013 by Dr. Craig Crews, a Yale professor and executive director of its Center for Molecular Discovery. The idea was to leverage his breakthroughs in therapies that degrade disease-causing proteins. CEO John Houston came aboard in 2017.